Edgewise Therapeutics (EWTX) has seen its stock price skyrocket recently, with its novel treatment for hypertrophic cardiomyopathy (HCM) showing promising results in early trials. The company also boasts a strong pipeline of other potential therapies, and investors are increasingly optimistic about its future prospects. While volatility is expected due to the experimental nature of the treatment, Edgewise’s strong financial position and growing institutional support suggest a bright future.